ArticleEJHaem2024

CD19-targeting chimeric antigen receptor T-cell therapy is safe and effective for intra-cardiac B cell non-Hodgkin lymphoma.

Daniel H Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.